Citations

Clear

15 citation(s) found for "Sciallis, GF".

Solitary Fibrous Tumor of Breast and Axilla: Clinicopathological Profile of Five Tumors With Comparison of Risk Stratification Models
Hoda, Raza S. , Duckworth, Lauren A. , Gilmore, Hannah , Cui, Xiaoyan , Arnam, John S. Van , Zhang, Gloria, Rowe, J. Jordi, Xiao, Huijun , Azzato, Elizabeth M. , Goldblum, John R. , Fritchie, Karen , Downs, Erinn, Fritchie, Karen J , Downs, Erinn P, Hoda, Raza S , McIntire, Patrick J. , Sciallis, Andrew P. , Xiao, Huijun

Mayo Clinic

International Journal of Surgical Pathology | October 30, 2023 | Volume: 32 | Issue: 5 | Pages: 895-907

10.1177/10668969231204957 | PMID 37899729 Get It

Introduction: Solitary fibrous tumor (SFT) is a fibroblastic tumor with malignant potential that is underpinned by a recurrent inv12(q13q13)-derived NAB2::STAT6 fusion. Breast and axilla are uncommon locations for this entity. Methods: Records of two academic institutions were electronically searched for breast and axillary SFTs. Clinical and pathologic data were reviewed. Literature review for breast or axillary SFTs was performed. Present study and previously reported tumors were stratified using five SFT risk models: original and modified Demicco metastatic risk, Salas local recurrence risk, Salas metastatic risk, and Thompson local recurrence risk. Results: Five patients with breast or axillary SFT were identified. Median age was 49 years, and median follow-up (available for four patients) was 82 months. Three patients showed no evidence of disease, and one developed recurrence. Literature review identified 58 patients with breast or axillary SFT. Median age was 54 years, and median follow-up (available for 35 patients) was 24 months. Thirty-one patients showed no evidence of disease, three developed recurrence, and one developed metastasis. Original and modified Demicco models and Thompson model showed the highest sensitivity; original and modified Demicco models and Salas metastatic risk model demonstrated the highest specificity. Kaplan–Meier models were used to assess recurrence-free probability (RFP). Original and modified Demicco models predicted RFP when stratified by “low risk” and “moderate/intermediate and high risk” tumor, though sample size was small. Conclusions: While many SFTs of breast and axilla remain indolent, a subset may develop recurrence and rarely metastasize. The modified Demicco risk model demonstrated optimal performance characteristics.
Low‐grade adenosquamous carcinoma of the breast: a clinical, morphological and immunohistochemical analysis of 25 patients
Lewis, Gloria J., Fong, Nancy, Gjeorgjievski, Sandra Gjorgova , Li, Xiaoxian , Li, Zaibo , Wei, Shi, Sturgis, Charles D. , Wang, Chunjie , Komforti, Miglena K. , Downs, Erinn, Cui, Xiaoyan , Rowe, J. Jordi, Zhang, Gloria, Komforti, Miglena, Hoda, Raza S , Zhang, Gloria , Lewis, Gloria, Zhang, Huina , McIntire, Patrick J. , Hoda, Raza S. , Sciallis, Andrew P.

Mayo Clinic

Histopathology | April 17, 2023 | Volume: 83 | Issue: 2 | Pages: 252-263

10.1111/his.14917 | PMID 37067767 Get It

AimsDue to its rarity and non‐specific clinical and pathological features, low‐grade adenosquamous carcinoma (LGASC) of the breast continues to pose diagnostic challenges. Unlike other triple‐negative breast carcinomas, LGASC tends to have an indolent clinical behaviour. It is essential to recognise this lesion for accurate diagnosis and appropriate management.Methods and resultsTwenty‐five cases of LGASC were identified in our archives and collaborating institutes. Cases of LGASC with dominant coexisting other type carcinomas were excluded. We studied the clinical presentation, morphological features, patterns of the commonly used immunohistochemical stains and follow‐up. In our cohort, LGASC was commonly located at the outer aspect of the breast and associated with intraductal papilloma. The morphology of LGASC is characterised by infiltrating small glands and nests with variable squamous differentiation. We also found cuffing desmoplastic (fibrolamellar) stromal change in 75% of patients and peripheral lymphocytic aggregates in 87.5% of patients. P63 and smooth muscle myosin (SMM) were the most common myoepithelial markers used to assist in diagnosis. P63 often stained peripheral tumour cells surrounding invasive glands (circumferential staining in 80% of the cases), mimicking myoepithelial cells. It also stained the small nests with squamous differentiation. However, SMM was negative in 63% of the cases. The vast majority of our cases were triple‐negative; only a few had focal and weak expressions of ER and PR. One patient who did not have excision developed lymph node metastasis. Most patients underwent excision or mastectomy with negative margins as surgical treatment; there were no recurrences or metastases in these patients with clinical follow‐ups up to 108 months.ConclusionsLGASC has some unique, although not entirely specific, morphological features and immunohistochemical staining patterns. Fibrolamellar stromal change, peripheral lymphocytic aggregates and variable staining of p63 and SMM are valuable features to facilitate the diagnosis.
An innovative systems perspective of protein-protein interactions in the physiologic T cell antigen receptor signaling network (TECH2P.929)
Neier, Steven C. , Smith, Stephen , Davis, Tessa R. , Nevala, Wendy K. , Markovic, Svetomir, Eckel‐Passow, Jeanette E. , Sciallis, Gabriel F., Wieland, Carilyn N. , Torgerson, Rochelle R. , Sinnwell, Jason P. , Enninga, Elizabeth Ann L. , Markovic, Svetomir N. , Neuhauser, Claudia , Schrum, Adam G.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 194 | Issue: 1_Supplement | Pages: 206.39-206.39

10.4049/jimmunol.194.supp.206.39 Get It

Abstract Signaling networks and the protein interactions that define them are of great interest, but techniques to assess these networks in unmanipulated primary human cells are limited. We have developed and applied a novel technological and analytical platform to measure proteins in shared complexes detected by exposed surface epitopes (PiSCES). Immunoprecipitation reactions are performed in multiplex using microsphere beads to measure 20+ proteins and 210+ distinct pair-wise protein associations that are important for T cell antigen receptor signaling. Jurkat T cells stimulated with superantigen generated an extensive PiSCES signature using this method and provided a dataset from which we optimized an analytical package. The system is currently being utilized to address the hypothesis that T cells isolated from skin lesions of autoimmune alopecia areta (AA) patients will have a unique PiSCES signature compared to those isolated from non-AA donors. To investigate this, we have isolated non-engineered primary cells from AA patient skin lesions and healthy controls, and have begun to identify differences in their PiSCES signatures, either directly after isolation or after stimulation with anti-CD3 and anti-CD28. We conclude that this novel PiSCES approach is capable of generating protein-protein interaction signatures that provide a unique view of TCR signalosome activity solicited from physiologic non-engineered primary human patient samples.
The diagnostic criteria of pityriasis rosea and Gianotti-Crosti syndrome – a protocol to establish diagnostic criteria of skin diseases
Chuh, Antonio , Zawar, Vijay , Sciallis, GF, Lee, A

Mayo Clinic

Journal of the Royal College of Physicians of Edinburgh | June 27, 2022 | Volume: 45 | Issue: 3 | Pages: 218-225

10.4997/jrcpe.2015.310a Get It

Acneiform Presentations of Folliculotropic Mycosis Fungoides
Shamim, Huma, Riemer, Christie , Weenig, Roger H., Sokumbi, Olayemi , Sciallis, Gabriel F., McEvoy, Marian T., Mischke, Daniel, Comfere, Nneka I. , Sciallis, Gabriel, McEvoy, Marian, Sokumbi, Olayemi

Mayo Clinic

The American Journal of Dermatopathology | January 24, 2021 | Volume: 43 | Issue: 2 | Pages: 85-92

10.1097/dad.0000000000001698 | PMID 33492839 Get It

Background: Folliculotropic mycosis fungoides (FMF) is a variant of cutaneous T-cell lymphoma that has clinical overlap with a variety of inflammatory follicular unit disorders. However, we describe distinctive presentations of FMF with acneiform features that can be diagnostically challenging, leading to diagnostic delay. Objective: To highlight the importance of histopathologic and immunohistochemical evaluation for diagnostic confirmation of presumed inflammatory follicular unit–based disorders that are unusual in presentation or unresponsive to standard therapies. Methods: A cross-sectional retrospective study of 5 consecutive patients with a histopathologic diagnosis of FMF was conducted. The clinical, histopathologic, immunophenotypic, and molecular genetic features of cases are presented. Results: We describe 5 patients with clinical and histopathologic presentations of FMF masquerading as hidradenitis suppurativa, furunculosis, or acne vulgaris (age range 34–66 years, 4:1 female to male). Clinical morphologies included open and closed comedones, inflammatory pustules, papules and nodules, follicular papules with keratotic plugging, cysts, and scarring involving the face, trunk, and intertriginous areas. All patients failed to respond to standard therapies, including topical and oral antibiotics, topical and oral retinoids, or topical corticosteroids, before receiving the diagnosis of FMF. Lesional skin biopsies showed a perifollicular CD4-positive T-lymphocytic infiltrate with pilotropism, intrafollicular mucin deposition, foreign-body granulomatous inflammation, acute inflammation, and follicular epithelial necrosis. None had concurrent systemic mycosis fungoides. Limitations: Small retrospective cohort study. Conclusion: We present these cases to expand the clinical and histopathologic spectrum of FMF that may strikingly resemble acneiform disorders and to highlight the importance of diagnostic reconsideration with histopathologic evaluation.
Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017
Roberts, Erin , Nowsheen, Somaira , Davis, Mark D. P. , McEvoy, M., Newman, Catherine C., Sartori‐Valinotti, Julio C. , Sciallis, Gabriel F., Torgerson, Rochelle R. , Wetter, David A. , Nowsheen, Somaira , Davis, Mark D.P.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | February 20, 2020 | Volume: 34 | Issue: 9 | Pages: 2106-2110

10.1111/jdv.16302 | PMID 32078195 Get It

AbstractBackgroundFew large studies have assessed spironolactone treatment of adult female acne.ObjectivesTo explore the role of spironolactone in the treatment of adult female acne.MethodsWe performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017.ResultsIn total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two‐thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long‐term treatment with spironolactone (median duration, 13 months) and had few adverse effects.ConclusionsSpironolactone is a safe and effective treatment of acne for women.
Red tattoo‐related mycosis fungoides‐like CD8+ pseudolymphoma
King, Brian J. , Lehman, Julia S. , Macon, William R. , Sciallis, Gabriel F., Lehman, Julia S

Mayo Clinic

Journal of Cutaneous Pathology | November 29, 2017 | Volume: 45 | Issue: 3 | Pages: 226-228

10.1111/cup.13089 | PMID 29193201 Get It

Cutaneous reactions to red tattoo pigment rarely manifest as pseudolymphomatous reactions. We describe an exceedingly rare case of red tattoo‐related T‐cell predominant pseudolymphoma microscopically mimicking mycosis fungoides. Careful clinicopathological correlation was required to obtain the correct diagnosis and aid in an effective treatment course.
The diagnostic criteria of pityriasis rosea and Gianotti-Crosti syndrome – a protocol to establish diagnostic criteria of skin diseases
Chuh, Antonio , Zawar, Vijay , Sciallis, GF, Lee, A, Sciallis, GF

Mayo Clinic

Journal of the Royal College of Physicians of Edinburgh | April 24, 2017 | Volume: 45 | Issue: 3 | Pages: 218-225

10.4997/jrcpe.2015.310 | PMID 26517103 Get It

We established and validated diagnostic criteria for pityriasis rosea and Gianotti-Crosti syndrome. In this paper, we compare and contrast both diagnostic criteria to formulate a protocol in establishing diagnostic criteria for other dermatological diseases. The diagnostic criteria are similar in employing clear dividing lines and conjunctions (‘and/or') to assure high reliability. Both sets of criteria should be applicable for all ethnic groups. Spontaneous remission is not included, so diagnosis is not delayed while waiting for disease remission. Laboratory investigations are not enlisted, so that the criteria can be used in medical care systems in different parts of the world. The diagnostic criteria are different in that pathognomonic clinical manifestations exist for pityriasis rosea, such as the herald patch and the orientation of lesions along the lines of skin cleavages. These features, however, score low for sensitivity. These specific manifestations are not seen in Gianotti-Crosti syndrome. Such differences led to different categorisation of clinical features. Atypical variants are more common for pityriasis rosea. The diagnostic criteria for pityriasis rosea therefore do not include a list of differential diagnoses, while diagnostic criteria for Gianotti-Crosti syndrome do. Using this comparison, we constructed a protocol to establish diagnostic criteria for other skin diseases. We advocate the need to justify the establishment of diagnostic criteria, that multiple diagnostic criteria for the same disease should be avoided, that diagnostic criteria should be compatible with the disease classification if applicable, and that the scope should be well-delineated with regard to clinical variants. We outline the need for validation studies to assess the criteria-related validity, test-retest intra-clinician reliability, and inter-clinician reliability. We emphasise that the establishment of diagnostic criteria should not be a generic process. We also highlight limitations of diagnostic criteria, and emphasise that no diagnostic criteria can replace the bedside experience of clinicians.
Multiplex matrix network analysis of protein complexes in the human TCR signalosome
Smith, Stephen , Neier, Steven C. , Reed, Brendan , Davis, Tessa R. , Sinnwell, Jason P. , Eckel‐Passow, Jeanette E. , Sciallis, Gabriel F., Wieland, Carilyn N. , Torgerson, Rochelle R. , Gil, Diana , Neuhauser, Claudia , Schrum, Adam G. , Smith, Stephen E P, Reed, Brendan K, Neuhauser, Claudia , Schrum, Adam G , Sinnwell, Jason P

Mayo Clinic

Science Signaling | August 2, 2016 | Volume: 9 | Issue: 439 | Pages: No page available

10.1126/scisignal.aad7279 | PMID 27485017 Get It

A multiplex antibody-mediated capture technique reveals patient-specific protein complexes.
A position statement on the management of patients with pityriasis rosea
Chuh, Antonio , Zawar, Vijay , Sciallis, Gabriel F., Kempf, Werner

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | July 13, 2016 | Volume: 30 | Issue: 10 | Pages: 1670-1681

10.1111/jdv.13826 | PMID 27406919 Get It

AbstractMany clinical trials have been conducted on the treatment of pityriasis rosea (PR). Our aim was to establish a position statement for the management of adults withPRbased on the best available evidence. We searchedPubMedfor all reports on randomized controlled trials for the treatment ofPRpublished in the past 30 years. We retrieved 14 articles reporting randomized controlled trials, and found five which met our quality requirements for in‐depth analyses. Erythromycin was found in a well‐conducted triple‐blind study to cast significant impacts on clinical outcomes. However, adverse gastrointestinal effects were fairly common. Another well‐conducted study on azithromycin reported no significant benefit. It was reported in three well‐conducted studies on oral acyclovir in low dose (400 mg three times daily for 7 days or 400 mg five times daily for 7 days) and high dose (800 mg five times daily for 7 days), that acyclovir is effective in attaining rash regression and lessening the pruritus. When compared against each other, the high‐dose regimen demonstrated no benefit over the low‐dose regimens. Our statement comprises the follows: (i) The diagnosis ofPRshould be ascertained; (ii) The patients should be assessed for rash severity and impacts on quality of life; (iii)PRis a self‐limiting disease, and most patients do not necessitate any treatment; (iv) For patients necessitating active treatment, oral acyclovir as 400 mg three times daily for 7 days can be considered; (v) Attention should be given to adverse effects and contraindications of acyclovir; (vi) WhenPRoccurs in early pregnancy, oral antiviral therapy could be considered after consulting experienced clinicians; (vii) Inadequate information exists in the use of acyclovir to treatmentPRin children and breastfeeding women; and (viii) TreatingPRis an off‐label use of acyclovir, and this has to be discussed with experienced colleagues and the patients.